Table of Contents
ISRN Urology
Volume 2011, Article ID 545241, 8 pages
http://dx.doi.org/10.5402/2011/545241
Review Article

Metastatic Bladder Cancer: A Review of Current Management

1Department of Palliative and Supportive Care, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
2Department of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
3The University of Manchester, Oxford Road, Manchester, M13 9PL, UK

Received 16 February 2011; Accepted 6 April 2011

Academic Editor: A. M. El-Assmy

Copyright © 2011 Andrew Fletcher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Office of National Statistics, “Cancer registration statistics England 2008,” 2010. http://www.statistics.gov.uk.
  2. ICD online. Cancer in Scotland 2010, http://isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/.
  3. Northern Ireland Cancer Registry Bladder Cancer, 2010, http://www.qub.ac.uk/research-centres/nicr/Data/OnlineStatistics.
  4. Cancer incidence in Wales 2004–2008, 2010, http://www.wales.nhs.uk.
  5. Office of national Statistics, “Mortality Statistics: deaths registered in England and Wales,” 2010, http://www.statistics.gov.uk.
  6. M. J. Droller, Bladder Cancer—Current Diagnosis and Treatment, Human Press, 2001.
  7. C. N. Sternberg, P. H. M. de Mulder, J. H. Schornagel et al., “Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924,” Journal of Clinical Oncology, vol. 19, no. 10, pp. 2638–2646, 2001. View at Google Scholar · View at Scopus
  8. H. Von der Maase, S. W. Hansen, J. T. Roberts et al., “Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3068–3077, 2000. View at Google Scholar · View at Scopus
  9. T. H. Ecke, H. Gerullis, P. Bartel, S. Koch, and J. Ruttloff, “Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium,” Minerva Urologica e Nefrologica, vol. 61, no. 1, pp. 1–8, 2009. View at Google Scholar · View at Scopus
  10. J. Bellmunt, A. Ribas, N. Eres et al., “Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma,” Cancer, vol. 80, no. 10, pp. 1966–1972, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Dogliotti, G. Cartenì, S. Siena et al., “gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial,” European Urology, vol. 52, no. 1, pp. 134–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Dreicer, J. Manola, B. J. Roth et al., “Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group,” Cancer, vol. 100, no. 8, pp. 1639–1645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Carles, E. Esteban, M. Climent et al., “Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer,” Annals of Oncology, vol. 18, no. 8, pp. 1359–1362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Bellmunt, C. Théodore, T. Demkov et al., “Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4454–4461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Joly, N. Houédé, and S. Noal, “Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study,” Clinical Genitourinary Cancer, vol. 7, no. 2, pp. E28–E33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Fechner, R. Siener, M. Reimann, L. Kobalz, and P. Albers, “Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99),” International Journal of Clinical Practice, vol. 60, no. 1, pp. 27–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. J. Sweeney, B. J. Roth, F. F. Kabbinavar et al., “Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3451–3457, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. A. Hussain, G. R. MacVicar, D. P. Petrylak et al., “Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2218–2224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Wulfing, J. P. H. Machiels, D. J. Richel et al., “A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma,” Cancer, vol. 115, no. 13, pp. 2881–2890, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. M. Hahn, W. M. Stadler, R. Zon et al., “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1525–1530, 2011. View at Google Scholar
  21. J. E. Rosenberg, S. Halabi, B. L. Sanford et al., “Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207,” Annals of Oncology, vol. 19, no. 5, pp. 946–950, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Gomez-Abuin, E. Winquist, W. M. Stadler et al., “A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia,” Investigational New Drugs, vol. 25, no. 2, pp. 181–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium, 2010, http://clinicaltrials.gov/ct/show/NCT00363883.
  24. Vorinostat Plus Radiation Therapy in Pancreatic Cancer, 2010, http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=634674&version=HealthProfessional&protocolsearchid=7865385.
  25. Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, 2010, http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=651321&version=HealthProfessional&protocolsearchid=7865385.
  26. Phase I Study of Chemoradiotherapy Comprising Capecitabine and Vorinostat in Patients With Nonmetastatic Pancreatic Cancer, 2010, http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=655043&version=HealthProfessional&protocolsearchid=7865385.
  27. A. H. Ree, S. Dueland, S. Folkvord et al., “Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study,” The Lancet Oncology, vol. 11, no. 5, pp. 459–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Peyromaure, F. Scotté, D. Amsellem-Ouazana, A. Vieillefond, S. Oudard, and P. Beuzeboc, “Trastuzumab (Herceptin(TM)) in metastatic transitional cell carcinoma of the urinary tract: report on six patients,” European Urology, vol. 48, no. 5, pp. 771–775, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Beuzeboc, E. Banu, E. Voog et al., “Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study,” Journal of Clinical Oncology, vol. 25, article 15565, no. 18S, 2007. View at Google Scholar
  30. D. Cameron, “Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer,” Clinical Advances in Hematology and Oncology, vol. 5, no. 6, pp. 456–458, 2007. View at Google Scholar · View at Scopus
  31. B. H. Bochner, R. J. Cote, N. Weidner et al., “Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis,” Journal of the National Cancer Institute, vol. 87, no. 21, pp. 1603–1612, 1995. View at Google Scholar · View at Scopus
  32. G. M. Duchesne, J. J. Bolger, G. O. Griffiths et al., “A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09,” International Journal of Radiation Oncology, vol. 47, no. 2, pp. 379–388, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. D. B. McLaren, D. Morrey, and M. D. Mason, “Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly,” Radiotherapy & Oncology, vol. 43, no. 2, pp. 171–174, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. J. R. Yarnold, “8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party,” Radiotherapy & Oncology, vol. 52, no. 2, pp. 111–121, 1999. View at Google Scholar
  35. E. Steenland, J. W. Leer, H. van Houwelingen et al., “The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study,” Radiotherapy & Oncology, vol. 52, no. 2, pp. 101–109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. W. F. Harstell, C. B. Scott, D. W. Bruner et al., “Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases,” Journal of the National Cancer Institute, vol. 97, no. 11, pp. 798–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. S. K. Sarkar, S. Sarkar, B. Pahari, and D. Majumdar, “Multiple and single fraction palliative radiotherapy in bone secondaries - A prospective study,” Indian Journal of Radiology and Imaging, vol. 12, no. 2, pp. 281–284, 2002. View at Google Scholar · View at Scopus
  38. W. M. Sze, M. Shelley, I. Held et al., “Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy,” Cochrane Database of Systematic Reviews, no. 2, 2004. View at Google Scholar · View at Scopus
  39. G. N. Hortobagyi, R. L. Theriault, A. Lipton et al., “Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group,” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2038–2044, 1998. View at Google Scholar
  40. N. Norio Kohno, K. Aogi, H. Minami et al., “Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3314–3321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Saad, D. M. Gleason, R. Murray et al., “Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer,” Journal of the National Cancer Institute, vol. 96, no. 11, pp. 879–882, 2004. View at Google Scholar · View at Scopus
  42. M. S. Zaghloul, R. Boutrus, H. El-Hossieny, Y. A. Kader, I. El-Attar, and M. Nazmy, “A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer,” International Journal of Clinical Oncology, vol. 15, no. 4, pp. 382–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. R. Berenson, A. Lichtenstein, L. Porter et al., “Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 593–602, 1998. View at Google Scholar
  44. Summary of Product Characteristics. Zometa 4 mg/5ml Concentrate for Solution for Infusion, 2010, http://www.medicines.org.uk.
  45. Guidance on Cancer Services. Improving Outcomes in Urological Cancers. The Manual. National Institute of Clinical Excellence, 2002.
  46. R. D. Brierly and T. S. O'Brien, “The importance of palliative care in urology,” Urologia Internationalis, vol. 80, no. 1, pp. 13–18, 2008. View at Publisher · View at Google Scholar · View at Scopus